Zacks Research Issues Positive Outlook for SRPT Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Stock analysts at Zacks Research lifted their Q2 2025 earnings per share estimates for shares of Sarepta Therapeutics in a research note issued on Monday, October 21st. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will earn $2.09 per share for the quarter, up from their prior estimate of $2.08. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $1.45 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q3 2025 earnings at $2.10 EPS, Q4 2025 earnings at $2.18 EPS, FY2025 earnings at $8.17 EPS and Q1 2026 earnings at $2.80 EPS.

Several other research analysts have also recently weighed in on the company. Barclays lowered their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Jefferies Financial Group initiated coverage on Sarepta Therapeutics in a report on Monday. They set a “buy” rating and a $165.00 target price on the stock. Cantor Fitzgerald reissued a “neutral” rating and set a $152.00 target price on shares of Sarepta Therapeutics in a report on Friday, September 20th. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Finally, Piper Sandler reduced their target price on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $182.95.

Sarepta Therapeutics Stock Up 1.1 %

SRPT stock opened at $129.88 on Wednesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The stock has a market capitalization of $12.28 billion, a price-to-earnings ratio of 1,180.73 and a beta of 0.82. The business’s fifty day moving average price is $128.87 and its two-hundred day moving average price is $132.42. Sarepta Therapeutics has a fifty-two week low of $55.25 and a fifty-two week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.06. The firm had revenue of $362.90 million for the quarter, compared to analysts’ expectations of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The company’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.27) EPS.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds have recently added to or reduced their stakes in SRPT. Farallon Capital Management LLC increased its holdings in Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after purchasing an additional 1,243,427 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Sarepta Therapeutics by 693.7% in the second quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock worth $57,356,000 after purchasing an additional 317,277 shares in the last quarter. Canada Pension Plan Investment Board increased its holdings in Sarepta Therapeutics by 2,257.8% in the first quarter. Canada Pension Plan Investment Board now owns 240,500 shares of the biotechnology company’s stock worth $31,135,000 after purchasing an additional 230,300 shares in the last quarter. Rhumbline Advisers increased its holdings in Sarepta Therapeutics by 146.3% in the second quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company’s stock worth $42,809,000 after purchasing an additional 160,942 shares in the last quarter. Finally, Blair William & Co. IL increased its holdings in Sarepta Therapeutics by 303.7% in the second quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company’s stock worth $27,537,000 after purchasing an additional 131,112 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael Andrew Chambers acquired 37,038 shares of the stock in a transaction dated Friday, August 16th. The shares were bought at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.